BioPharma Dive June 20, 2024
Jonathan Gardner

One-year study data showing PTC’s pill suppressed a key protein helped persuade the regulator to remove a partial clinical hold it had put in place in 2022.

Dive Brief:

  • PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the U.S., following the Food and Drug Administration’s review of data showing the pill reduced a mutant protein linked to the disorder.
  • The drug, called PTC518, suppressed levels of huntingtin protein in both the blood and the cerebrospinal fluid by 43% in patients who took a once-daily 10 milligram dose over 12 months, PTC said. The company had previously disclosed data showing that dose reduced blood levels by around 30% through 12 weeks.
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Podcast: New Alzheimer's Drug Approval Expands Treatment Options – and Creates Coverage Questions
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
FDA Clears Emerging Brain PET System
STAT+: Applesauce lead contamination could not have been prevented, top FDA official suggests
Trump’s FDA commissioner on regulating AI

Share This Article